Key result
Anti-Xa and viscoelastic testing improve anticoagulation stability and reduce bleeding compared to ACT or aPTT in ECMO.
Why the study?
Anticoagulation monitoring in ECMO is complicated by patient factors and ECMO-induced coagulopathies, while differences in accuracy, turnaround time, and clinical utility across traditional and emerging monitoring assays impact their cost-effectiveness.
Answers are grounded in this paper and cite their sources.
This narrative review highlights that while anti-Xa and viscoelastic testing (TEG/ROTEM) are more expensive than traditional ACT and aPTT for monitoring unfractionated heparin during ECMO, they may reduce thrombotic and hemorrhagic complications and potentially lower overall ECMO costs.
Anticoagulation monitoring is crucial in managing critically ill patients, especially in settings such as extracorporeal membrane oxygenation (ECMO), where optimal anticoagulation is necessary to prevent clotting complications while avoiding bleeding risks.Factors like patient age, underlying conditions, and ECMO-induced coagulopathies complicate management.Unfractionated heparin (UFH) remains the most commonly used anticoagulant and is monitored via activated clotting time (ACT) or activated partial thromboplastin time (aPTT).Apart from these, other methodologies, such as anti-factor Xa (anti-Xa) assays, viscoelastic assays (VEA) like thromboelastography (TEG), and rotational thromboelastometry (ROTEM), are employed to guide heparin therapy.Each method offers distinct advantages, with ACT providing rapid point-of-care (POC) assessment, aPTT being widely accessible, anti-Xa assays offering direct heparin concentration measurement, while TEG/ROTEM provide comprehensive viscoelastic hemostatic profiles.However, differences in accuracy, turnaround time, and clinical utility impact their cost-effectiveness.Anti-Xa and viscoelastic testing (VET), though more expensive, may reduce thrombotic/hemorrhagic complications, potentially lowering overall ECMO cost.This article explores anticoagulation monitoring practices in ECMO, focusing on both traditional and emerging approaches, highlighting their advantages, limitations, and economic implications to optimize patient outcomes.
No takes yet. Share an insight, caveat, or question.
Borse et al. (2026) conducted a review in Severe cardiac or respiratory failure requiring extracorporeal membrane oxygenation (ECMO). Advanced and multimodal anticoagulation monitoring (anti-factor Xa assays, thromboelastography [TEG], rotational thromboelastometry [ROTEM]) vs. Traditional anticoagulation monitoring (activated clotting time [ACT] and activated partial thromboplastin time [aPTT]) was evaluated. Anti-factor Xa and viscoelastic testing (TEG/ROTEM) improve anticoagulation stability and reduce bleeding, transfusions, and circuit exchanges in ECMO compared to ACT or aPTT.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: